CAPTRUST Financial Advisors
SWTX

CAPTRUST Financial Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-119
Closed -$3K – 3821
2022
Q2 		$3K Buy
119
+26
+28% +$951 ﹤0.01% 4339
2022
Q1 		$5K Sell
93
-66
-42% -$3.78K ﹤0.01% 4171
2021
Q4 		$10K Buy
+159
New +$10.5K ﹤0.01% 3725
2021
Q3 		– Sell
-126
Closed -$10K – 4756
2021
Q2 		$10K Buy
126
+92
+271% +$6.99K ﹤0.01% 3554
2021
Q1 		$3K Buy
+34
New +$2.66K ﹤0.01% 3940

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

CAPTRUST Financial Advisors's SWTX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2022, closing a stake of 119 shares — an estimated $3K sold.

CAPTRUST Financial Advisors first reported a position in SWTX in Q1 2021 and held it in 5 quarters. The position peaked at $10K in Q4 2021. 148 funds tracked by Wall St. Rank hold SWTX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 119 SpringWorks Therapeutics shares in Q3 2022, an estimated $3K.
  • CAPTRUST Financial Advisors first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's SpringWorks Therapeutics position peaked at $10K in Q4 2021.
  • 148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.